ARS Pharmaceuticals
SPRY----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: ARS Pharmaceuticals(SPRY) predict that the Revenue is 22.68 M (+184.5%), Beat estimate;the EBIT is -60.15 M (-61.78%), Miss estimate;the EPS is -0.61 (-74.29%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B184.47%
0.02B177.39%
+0.00B7.08%
EBITMiss expectations
-0.06B61.78%
-0.05B36.27%
-0.01B25.51%
EPSMiss expectations
-0.6174.29%
-0.5351.43%
-0.080022.86%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf